Weight Loss — 2026-10-19
"Switching from Ozempic to reta" and "Wegovy to reta" are among the fastest-growing questions in metabolic peptide research. The reason is simple: researchers who have modeled a single GP-1 axis with sema are now asking what changes when they move to a triple agonist. This article covers what each compound is, why the switch is not a 1:1 dose swap, how washout and titration are handled in the literature, and what to expect on the other side.
Sourcing note for researchers: code PLATINUM25 at checkout unlocks 25% off reta 10mg and reta 20mg vials, plus sema 10mg — all batch-matched with full COAs.
Both brands are sema. Ozempic is the type 2 diabetes label (0.5–2 mg weekly); Wegovy is the chronic weight management label (up to 2.4 mg weekly). The active ingredient is identical — only the dose ceiling and indication differ. Sema is a single GP-1 receptor agonist with roughly a 7-day half-life.
Reta is a triple agonist at the GP-1, GIP, and glucagon receptors. Where sema only suppresses intake (appetite, gastric emptying), reta adds a glucagon arm that raises energy expenditure and hepatic fat oxidation. In Phase 2 data, reta's top dose produced roughly 24% weight loss versus sema's ~15% at the Wegovy dose — the magnitude gap is what motivates the switch. For the full mechanism breakdown, see reta vs Ozempic and reta vs Wegovy.
The single most common mistake modeled in the literature is treating the switch as milligram-for-milligram. It is not. A researcher at 2.4 mg sema weekly does not move to 2.4 mg reta. Reta is started low and re-titrated from the bottom, because the GIP and glucagon arms change the tolerability curve entirely.
| Prior sema dose | Typical reta starting point (research models) |
| 0.25–1 mg weekly | 2 mg weekly reta, titrate up |
| 1.7–2.4 mg weekly | 2–4 mg weekly reta, titrate up |
The guiding principle: the GP-1 receptor tolerance a subject built on sema carries over partially, but the two novel receptor arms do not — so re-escalation from a low dose protects against the nausea spike. See the reta beginner dosing protocol for the standard titration ladder.
Because sema has a ~7-day half-life, meaningful plasma levels persist for 4–5 weeks after the last dose. In research models, two approaches appear:
A full multi-week washout is rarely modeled — the receptor overlap is on the same GP-1 axis, so the risk of additive effect is modest at low reta doses.
Most researchers transitioning in start on reta 10mg ($105, or $78.75 with code PLATINUM25) because the lower total load suits the re-titration phase. Those modeling extended protocols past the escalation window often move to reta 20mg ($179, $134.25 with PLATINUM25) for the better per-mg value. Compare the two in reta 10mg vs 20mg.
Switching from Ozempic or Wegovy to reta means switching from a single-receptor to a triple-receptor model — so re-titrate from a low dose rather than matching the old milligrams. A washout is optional, tolerability resets briefly, and the payoff is the added glucagon-driven energy expenditure sema never provided.
Code PLATINUM25 takes 25% off at checkout. Every reta vial ships batch-matched with a full COA.
Disclaimer: All information presented in this article is for educational and informational purposes only. Platinum Biolabs does not promote or endorse the use of peptides for human consumption. All products sold by Platinum Biolabs are intended strictly for laboratory and research use only. Consult a qualified healthcare professional before making any health-related decisions.